• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Surges Over 200 Points; Aaron's Shares Jump

    6/17/24 2:40:51 PM ET
    $AAN
    $ALLG
    $AVTE
    $MBIO
    Diversified Commercial Services
    Consumer Discretionary
    Automotive Aftermarket
    Consumer Discretionary
    Get the next $AAN alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging over 200 points on Monday.

    The Dow traded up 0.57% to 38,807.47 while the NASDAQ rose 1.22% to 17,904.35. The S&P 500 also rose, gaining, 0.95% to 5,483.45.

    Check This Out: Top 4 Risk Off Stocks That May Rocket Higher In Q2

    Leading and Lagging Sectors

    Consumer staples shares jumped by 1.5% on Monday.

    In trading on Monday, real estate shares fell by 0.6%.

    Top Headline

    The NY Empire State Manufacturing Index rose to -6 in June versus a reading of -15.6 in May and coming in better than market expectations of -12.50.

    Equities Trading UP
                           

    • Mustang Bio, Inc. (NASDAQ:MBIO) shares shot up 352% to $0.5852 after the company announced safety and efficacy data from the complete Waldenstrom Macroglobulinemia cohort of its Phase 1/2 clinical trial of MB-106, showing an overall response rate of 90% with one patient remaining in complete remission at 31 months.
    • Shares of Allego N.V. (NASDAQ:ALLG) got a boost, surging 128% to $1.6750 after the company and its majority shareholder, Meridiam, announced a transaction framework agreement under which Meridiam will launch a tender offer for all issued and outstanding Allego shares not owned by Meridiam, with the option to tender shares for $1.70 per share in cash.
    • The Aaron’s Company, Inc. (NYSE:AAN) shares were also up, gaining 33% to $10.01 after the company announced that it entered into a definitive agreement to be acquired by IQVentures Holdings.

    Equities Trading DOWN

    • Aerovate Therapeutics, Inc. (NASDAQ:AVTE) shares dropped 93% to $2.1450. Aerovate Therapeutics released topline results from the Phase 2b portion of the IMPAHCT Phase 2b/3 trial of AV-101, a dry powder inhaled formulation of imatinib, for pulmonary arterial hypertension (PAH).
    • Shares of Workhorse Group Inc. (NASDAQ:WKHS) were down 29% to $2.1450 as the stock begins trading on a split-adjusted basis. Workhorse announced a 1-for-20 reverse stock split of its common stock last week after shareholders approved the move at the company's annual meeting of stockholders in May.
    • Ovid Therapeutics Inc (NASDAQ:OVID) was down, falling 70% to $0.9756 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint

    Also Check This Out: How To Earn $500 A Month From Steelcase Stock Ahead Of Q1 Earnings Report

    Commodities

    In commodity news, oil traded up 1.8% to $79.89 while gold traded down 0.9% at $2,328.90.

    Silver traded down 0.3% to $29.38 on Monday, while copper fell 1.2% to $4.4435.

    Euro zone

    European shares were mixed today. The eurozone's STOXX 600 gained 0.09%, Germany's DAX rose 0.37% and France's CAC 40 gained 0.91%. Spain's IBEX 35 Index fell 0.30%, while London's FTSE 100 slipped 0.06%.

    Wages in the Eurozone increased 5.3% year-over-year in the first quarter, while hourly labor costs climbed by 5.1% annually in the quarter.

    Spain’s trade gap widened to EUR 4.7 billion in April from EUR 4.4 billion in the year-ago month. Italy's annual inflation rate came in unchanged at 0.8% in May.

    Asia Pacific Markets

    Asian markets closed lower on Monday, with Japan's Nikkei falling 1.83%, Hong Kong's Hang Seng Index declining 0.03% and China's Shanghai Composite Index dipping 0.55%.

    China’s retail sales climbed by 3.7% year-over-year in May, while industrial production rose by 5.6% year-over-year in May. China's new home prices fell by 3.9% year-over-year during the month of May. The People's Bank of China kept the interest rate unchanged at 2.50% during its recent meeting. Japanese core machinery orders slipped l 2.9% month-over-month to 885.3 billion yen in April.

    Economics

    The NY Empire State Manufacturing Index rose to -6 in June versus a reading of -15.6 in May and coming in better than market expectations of -12.50.

    Now Read This: This Analyst With 86% Accuracy Rate Sees Over 13% Upside In Alphabet – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts

    Get the next $AAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAN
    $ALLG
    $AVTE
    $MBIO

    CompanyDatePrice TargetRatingAnalyst
    Ovid Therapeutics Inc.
    $OVID
    12/11/2025$3.00Buy
    Roth Capital
    Ovid Therapeutics Inc.
    $OVID
    11/17/2025Outperform
    Leerink Partners
    Ovid Therapeutics Inc.
    $OVID
    10/9/2025$7.00Outperform
    Oppenheimer
    Ovid Therapeutics Inc.
    $OVID
    8/8/2025$3.00Buy
    B. Riley Securities
    Ovid Therapeutics Inc.
    $OVID
    6/18/2024Outperform → Perform
    Oppenheimer
    Aerovate Therapeutics Inc.
    $AVTE
    6/18/2024$27.00 → $2.00Outperform → In-line
    Evercore ISI
    Aerovate Therapeutics Inc.
    $AVTE
    6/18/2024Buy → Hold
    TD Cowen
    Aerovate Therapeutics Inc.
    $AVTE
    6/18/2024$35.00 → $2.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $AAN
    $ALLG
    $AVTE
    $MBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Griffin James Francis

    3 - Workhorse Group Inc. (0001425287) (Issuer)

    1/28/26 5:04:30 PM ET
    $WKHS
    Auto Manufacturing
    Industrials

    SEC Form 3 filed by new insider Zion William Scott

    3 - Workhorse Group Inc. (0001425287) (Issuer)

    1/28/26 5:04:07 PM ET
    $WKHS
    Auto Manufacturing
    Industrials

    Amendment: New insider Motive Gm Holdings Ii, Llc claimed ownership of 6,629,800 shares (SEC Form 3)

    3/A - Workhorse Group Inc. (0001425287) (Issuer)

    1/22/26 6:30:50 PM ET
    $WKHS
    Auto Manufacturing
    Industrials

    $AAN
    $ALLG
    $AVTE
    $MBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Ovid Therapeutics with a new price target

    Roth Capital initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $3.00

    12/11/25 9:12:49 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Ovid Therapeutics

    Leerink Partners initiated coverage of Ovid Therapeutics with a rating of Outperform

    11/17/25 9:41:02 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Ovid Therapeutics with a new price target

    Oppenheimer initiated coverage of Ovid Therapeutics with a rating of Outperform and set a new price target of $7.00

    10/9/25 8:28:36 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $ALLG
    $AVTE
    $MBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jin David bought $238 worth of shares (247 units at $0.96), increasing direct ownership by 633% to 286 units (SEC Form 4)

    4 - MUSTANG BIO, INC. (0001680048) (Issuer)

    12/30/25 4:15:14 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and COO Alexander Margaret A. bought $4,971 worth of shares (6,810 units at $0.73), increasing direct ownership by 24% to 34,935 units (SEC Form 4)

    4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

    1/29/25 9:18:08 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Gen Counsel/Corp Sec George Rachel G bought $4,240 worth of shares (500 units at $8.48), increasing direct ownership by 0.71% to 71,384 units (SEC Form 4)

    4 - Aaron's Company, Inc. (0001821393) (Issuer)

    7/10/24 8:03:11 AM ET
    $AAN
    Diversified Commercial Services
    Consumer Discretionary

    $AAN
    $ALLG
    $AVTE
    $MBIO
    SEC Filings

    View All

    Workhorse Group Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Workhorse Group Inc. (0001425287) (Filer)

    1/21/26 4:55:47 PM ET
    $WKHS
    Auto Manufacturing
    Industrials

    Workhorse Group Inc. filed SEC Form 8-K: Leadership Update

    8-K - Workhorse Group Inc. (0001425287) (Filer)

    1/12/26 4:19:32 PM ET
    $WKHS
    Auto Manufacturing
    Industrials

    SEC Form SCHEDULE 13G filed by Ovid Therapeutics Inc.

    SCHEDULE 13G - Ovid Therapeutics Inc. (0001636651) (Subject)

    1/8/26 11:56:04 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $ALLG
    $AVTE
    $MBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

    OV350 showed a good safety profile, supporting the advancement of the Company's KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no safety findings, and no treatment-related serious adverse events (SAEs)Exploratory quantitative electrophysiology results suggest OV350 had central activity and spectral power consistent with expected physiological effects of KCC2 modulation; aligned with expected drug exposure in the brainPharmacokinetics for OV350 were as predicted, and will inform dosing strategies for future KCC2 development programsOV4071 (oral) is on track for regulatory submission for a Phase 1/1b clinical trial in Q1 20

    12/18/25 8:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Workhorse Group and Motiv Electric Trucks Complete Merger, Creating a Leading North American Medium-Duty Electric Truck OEM

    Positioned to create value by offering broader portfolio of high performing commercial EVs at lower unit costs, targeting ~$23B medium-duty market1 Strengthened financial profile with access up to $50 million in new debt financing Combined company to be called Workhorse and trade on Nasdaq under "WKHS" Scott Griffith, Workhorse CEO, issues letter to shareholders highlighting strategic vision and go-forward priorities  WIXOM, Mich., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (NASDAQ:WKHS) ("Workhorse" or the "Company"), an American manufacturer of zero-emission commercial vehicles, and Motiv Electric Trucks ("Motiv"), a leading manufacturer of medium-duty electric trucks and

    12/15/25 4:35:00 PM ET
    $WKHS
    Auto Manufacturing
    Industrials

    Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

    NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid's leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance. Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regula

    12/2/25 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $ALLG
    $AVTE
    $MBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

    NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid's leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance. Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regula

    12/2/25 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

    NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including

    3/3/25 8:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

    NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development Officer. Dr. Banks will oversee Ovid's clinical development, medical, and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the Company's leadership team. Dr. Banks brings to Ovid broad and deep experience in neurology, clinical strategy, and business development. Her strategic acumen will serve Ovid at an important juncture for the Company as it determ

    8/8/24 8:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $ALLG
    $AVTE
    $MBIO
    Financials

    Live finance-specific insights

    View All

    Workhorse Group Reports Third Quarter 2025 Results

    CINCINNATI, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Workhorse Group, Inc. (NASDAQ:WKHS) ("Workhorse" or "the Company"), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today reported financial results for the third quarter ended September 30, 2025. Management Commentary "We continue to make important progress on our product roadmap at Workhorse," said Company CEO Rick Dauch. "We recently announced the availability of the Utilimaster Aeromaster body for our W56 Class 5/6 step van, designed to enhance the flexibility, durability, efficiency, and safety of the W56 platform. This exciting new offering will enable us to deliver the performan

    11/10/25 5:30:00 PM ET
    $WKHS
    Auto Manufacturing
    Industrials

    Workhorse Group Sets Third Quarter 2025 Earnings Call for Tuesday, November 11, 2025 at 10:00 a.m. ET

    CINCINNATI, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS) ("Workhorse" or "the Company"), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, will hold a conference call on Tuesday, November 11th at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) to discuss its financial results for the third quarter ended September 30, 2025 as well as the Company's plans and outlook. Financial results will be issued in a press release prior to the call. Workhorse management will host a presentation, followed by a question-and-answer period. Date: Tuesday, November 11, 2025Time: 10:00 a.m. Eastern time (7:00 a.m. Pacific time)

    11/5/25 4:05:00 PM ET
    $WKHS
    Auto Manufacturing
    Industrials

    Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

    An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor, vigabatrin (VGB), as measured on transcranial magnetic stimulation (TMS) 1Findings confirm OV329 penetrates the brain, engages the target and achieves biological modulation as expected of elevated levels of GABA, the major inhibitory neurotransmitterSafety and tolerability results are supportive of further development and appear to be preferable relative to marketed anti-seizure medicines (ASMs)Ovid plans to advance OV329 into a Phase 2a study in d

    10/3/25 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $ALLG
    $AVTE
    $MBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

    SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

    11/14/24 6:01:44 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

    SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

    11/14/24 4:39:42 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mustang Bio Inc.

    SC 13G/A - MUSTANG BIO, INC. (0001680048) (Subject)

    11/14/24 4:21:44 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $ALLG
    $AVTE
    $MBIO
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

    Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

    6/21/24 3:23:59 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care